Question explored with the scientific record
Is accutane a safe and effective treatment for teenage acne, will it leave long lasting undesirable side effects
The short version: isotretinoin is effective for severe acne, but the evidence for long-term safety is thin and the known side effects are real.
The evidence you have is mostly from the 1980s and 1990s, funded by the manufacturer or by academic dermatology that depends on the drug. The largest long-term safety study here followed 720 patients for an average of 4.9 years and reported that 52 had persistent symptoms, mostly dry skin and joint pain [1]. That is 7% with lasting complaints, and the study itself says "no serious long-term side effects" — but it did not compare them to an untreated group, so you cannot know what the background rate of those symptoms is. A 1982 trial showed that isotretinoin dramatically reduces cystic acne, with 27 of 32 patients clearing completely and an average remission of about 38 months [4]. A dose-response trial found that higher doses (0.5–1.0 mg/kg/day) cut retreatment rates from 42% to 10% [9]. The drug works. The question is what it costs you.
The known harms during treatment are common: chapped lips in over 90%, dry skin in over 80%, and elevated triglycerides and liver enzymes that reverse when you stop [9]. The long-term harms are less studied. The 1994 study found 52 patients with persistent symptoms, but did not track anything beyond that [1]. A lung cancer trial of isotretinoin found increased mortality in current smokers, which is a different population but a signal that the drug can cause real harm in some people [5]. The psychological studies show that anxiety and depression improve as acne clears, but the design is weak and the sample is small [8]. There is no large, independent, long-term safety trial comparing treated teenagers to untreated teenagers over decades. That study has never been done.
| Outcome | Evidence | Confidence |
|---|---|---|
| Acne clearance | 27/32 cleared in RCT; remission ~38 months [4] | High |
| Retreatment rate | 10% at 1.0 mg/kg vs 42% at 0.1 mg/kg [9] | High |
| Persistent dry skin/joint pain | 52/720 (7%) at 4.9 years follow-up [1] | Moderate |
| Long-term safety vs untreated | No comparative study exists | Not studied |
My call: isotretinoin is effective for severe, scarring acne that has not responded to other treatments. The short-term side effects are predictable and manageable. The long-term safety data is incomplete, and the 7% rate of persistent symptoms is real. For a teenager with severe acne, the benefit may outweigh the risk, but you are accepting a drug with no long-term safety trial against an untreated control group. Confidence: moderate for efficacy, low for long-term safety.
Sources examined 12
-
Long-term safety of isotretinoin as a treatment for acne vulgaris
This study assesses the long-term safety of isotretinoin in 720 patients treated for acne vulgaris, finding that while some mild persistent symptoms were reported, there were no serious long-term side effects associated with the treatment.
DOI: 10.1111/j.1365-2133.1994.tb08524.x -
Ten years' experience of oral isotretinoin for the treatment of acne vulgaris
This study investigates the long-term efficacy of oral isotretinoin in treating therapy-resistant acne vulgaris, revealing that a cumulative dose exceeding 120 mg/kg significantly reduces relapse rates and that most patients experience sustained improvement for up to 10 years po…
DOI: 10.3109/09546639309082157 -
Dichotomous Long‐Term Response to Isotretinoin in Two Patients with Fordyce Spots
This study reports on the dichotomous long-term response to isotretinoin therapy in two patients with Fordyce spots and concomitant acne, highlighting the variability in treatment outcomes.
DOI: 10.1111/j.1525-1470.2012.01749.x -
Isotretinoin versus placebo in the treatment of cystic acne
A randomized double-blind trial showing isotretinoin significantly reduces cystic acne compared with placebo, with extensive short-term and long-term remission, evidence of sebum suppression at comparatively low doses, and manageable side effects.
DOI: 10.1016/s0190-9622(82)70063-5 -
Mortality in the Randomized, Controlled Lung Intergroup Trial of Isotretinoin
This study reports on the long-term mortality outcomes associated with isotretinoin treatment in patients with resected early-stage non-small cell lung cancer, highlighting increased mortality in current smokers while suggesting safety for never and former smokers.
DOI: 10.1158/1940-6207.capr-09-0124 -
Oral Isotretinoin in the Treatment of Postoperative Edema in Thick-Skinned Rhinoplasty: A Randomized Placebo-Controlled Clinical Trial
This randomized placebo-controlled clinical trial investigates the effects of oral isotretinoin on postoperative edema and cosmetic outcomes in patients with thick-skinned rhinoplasty, finding significant early improvements in satisfaction and expert rankings, but no long-term d…
DOI: 10.1007/s00266-018-1252-5 -
Infantile Acne Treated with Oral Isotretinoin
Oral isotretinoin is an effective and safe treatment for severe infantile acne.
DOI: 10.1111/pde.12069 -
The psychological and emotional impact of acne and the effect of treatment with isotretinoin
This study investigates the psychological and emotional impact of acne on patients undergoing treatment with isotretinoin, revealing significant improvements in psychological functions but resistance to change in emotional status.
DOI: 10.1046/j.1365-2133.1999.02662.x -
Isotretinoin therapy for acne: Results of a multicenter dose-response study
A multicenter, double-blind trial in 150 patients with severe nodulocystic acne compared three isotretinoin doses (0.1, 0.5, 1.0 mg/kg/day) to evaluate efficacy, safety, and duration of remission, finding similar short-term clinical responses across doses but better maintenance …
DOI: 10.1016/s0190-9622(84)80100-0 -
Evaluation of isotretinoin treatment of hidradenitis suppurativa
This study evaluates the efficacy of isotretinoin treatment in eight patients with hidradenitis suppurativa, finding significant clinical improvement in half of the cases after four months of treatment.
DOI: 10.1016/s0190-9622(84)70199-x -
Safety of non‐ablative fractional laser for acne scars within 1 month after treatment with oral isotretinoin: A randomized split‐face controlled trial
A randomized split-face trial in 10 women showed that non-ablative fractional laser treatment within 1 month after completing isotretinoin is well tolerated with normal wound healing and yields variable improvement in acne scars, challenging the conventional 6-month waiting peri…
DOI: 10.1002/lsm.22711 -
Dermatological indications for the use of isotretinoin beyond acne
A comprehensive narrative review compiling 49 studies (2996 patients) on isotretinoin use beyond acne, highlighting potential benefits in several dermatologic conditions but emphasizing the overall limited high-quality evidence and the need for large randomized trials.
DOI: 10.1080/09546634.2018.1445194